Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Whole Genome Sequencing Analysis of Severe, Early-onset Chronic Obstructive Pulmonary Disease
Gharib, Salwa, Oelsner, E., Xu, Hanfei , Yu, Bing , Meyers, D.A., Norwood, Arnita F. , Ortega, V.E., Sliwiński, P, Medicine, Trans-Omics in Precision, Silverman, E.K., Cho, M.H. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Kim, Katherine Callaway , Hu, X., Chun, Sung , Rasmussen‐Torvik, Laura J. , Sofer, Tamar , Barr, R. Graham , Carson, April P. , Kalhan, Ravi , Kaplan, Robert C. , Lomas, David A. , London, Stephanie J. , Meyers, D.A., O’Connor, George T. , Psaty, Bruce M. , Rich, Stephen S. , Manichaikul, Ani

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3380-A3380

10.1164/ajrccm.2025.211.abstracts.a3380 Get It

Abstract Background:Chronic obstructive pulmonary disease (COPD) is a major global health burden, with genome-wide association studies explaining only a fraction of its heritability. Recent advancements, including large-scale, multi-ancestry whole-genome sequencing and a focus on severe, early-onset cases, offer promising avenues to identify additional COPD-related variants. Furthermore, recent studies show that adjusting for polygenic risk scores (PRS) enhances statistical power to detect rare variants, advancing efforts to understand COPD's genetic basis. Methods:We performed a whole genome sequencing association study of severe, early-onset COPD (FEV1 < 50%, age ≤ 55), FEV1 and FEV1/FVC in eight population-based studies (ARIC, CARDIA, CFS, CHS, FHS, HCHS/SOL, JHS, MESA) and seven COPD-enriched studies (COPDGene, ECLIPSE, Boston Early-Onset COPD Study, LTRC, TCGS (Poland), ICGN, SPIROMICS). We performed single-variant analyses using regenie software, applying a genome-wide significance threshold of P < 5.0 x 10-8. For rare variant set (MAF <1%) analysis, we annotated variants with loss of function or deleterious missense using WGS Annotator and prediction tools LOFTEE, SIFT, and PolyPhen2, then analyzed these variants with SKATO-ACAT method in regenie, adjusting for covariates including sex, sequencing center, and principal components of ancestry. We additionally evaluated adjusting the analyses for PRSs for lung function traits. Results: We analyzed 53,028 participants including 34,751 European, 12,508 African, 1,088 Latino American, and 674 East Asian ancestry. Across cohorts, we analyzed 5,063 severe (FEV1 < 50%) COPD cases, among whom 1,103 were early-onset (age ≤ 55). Excluding variants within 1 Mbp of known variants, single-variant analysis identified 68 novel associations (MAC ≥ 30), with 8 common associations (MAF ≥ 1%) in 6 genomic regions. Our most significant novel association for severe early-onset COPD was rs74297390 (intergenic to POM121L12, MAF = 9.6%, Beta = 0.41, P = 3.5 x 10-8). For FEV1 and FEV1/FVC ratio, variants near DKK2 and AKR1E2 were significantly associated and were replicated in an independent dataset (Shrine et al., 2019). DKK2 is an antagonist in the Wnt pathway. In a preliminary variant set analysis, CHRM3-AS1 was associated with severe early-onset COPD, GPAT with FEV1, and COL8A1I and HMCN1 with FEV1/FVC. With PRS adjustment, ST6GALNAC5 was associated with FEV1/FVC. Conclusions: In a whole genome sequencing study of lung function and severe early-onset COPD, we identified new loci for COPD-related phenotypes, including two novel loci that replicated in an independent dataset. Ongoing work involves variant set-based analyses with additional covariate adjustments, as well as PRS adjustments for binary traits.
Membrane Tension Gates Alveolar Type 1 Fate Selection
Gibbard, D., Ali, G., Ghelfi, Elisa , Guo, Min , Ali, G., Cai, J., Han, Y., Brownfield, Douglas

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3333-A3333

10.1164/ajrccm.2025.211.abstracts.a3333 Get It

Abstract RATIONALE: The alveolar epithelium consists of two cell types (AT2 and AT1) derived from a common Distal Progenitor (DP). Understanding how the epithelium of alveoli functions and becomes differentiated is essential for treatment of lung diseases. One possible regulator of cell fate is cell membrane tension (CMT), a biophysical property measured by the energy required to deform the membrane and known to be an important regulator of cell movement and endocytic processes. AT1 fate selection is largely driven and reinforced by YAP (Yes-associated protein), a mechano-sensitive transcription factor gated from entering the nucleus by the size of nuclear pores, which increases upon stretch. Here, we investigated whether and how CMT regulates the transduction of stretch-dependent YAP signaling and the remodeling into AT1 cells. METHODS: DPs were isolated from E15.5 mice and cultured on Matrigel for use in differentiation experiments. Immunostaining for AT1 and AT2 markers, Phalloidin, DAPI and YAP were used to assess YAP localization and architectural changes. We generated transgenic mice containing a pan-epithelial Cre (TgNkx2.1-Cre), a Cre-dependent driver of ltta (TigreAi140), and a TetOff regulated construct expressing YAP1 (Rosa26teto-Yap1), resulting in constitutive Yap1 expression in Cre-expressing DPs. CMT is measured both with optical trap technology and with the use of FlipTR dye, which uses Fluorescence Lifetime Imaging Microscopy (FLIM) to determine CMT. RESULTS: To demonstrate the role of CMT in timing AT1 fate, we found that CMT lowers in DPs concomitantly with differentiation, and that flattening cells (likely AT1s) have even lower CMT than round cells (likely AT2s). Using organotypic culture, we found that raising CMT with MBCD, PEG, or Matrigel embedding largely stops differentiation of DPs. Surprisingly, even when YAP is overdriven in mice in E15.5 distal progenitors, early precocious AT1 differentiation is not observed, suggesting YAP signaling is not alone sufficient to drive AT1 fate selection in DPs with higher CMT. We reproduced this finding when culturing DPs under high CMT conditions-promoting high YAP/TAZ levels via LATS inhibition was also not sufficient to select for AT1 fate. Finally, we found that high CMT disrupts nuclear YAP localization, nuclear-actin attachment, and cytoskeletal remodeling that is typically when DPs remodel towards AT1 fate. We propose that high baseline CMT in DPs prevents cellular remodeling, specifically that it suppresses the formation of actin-nuclear associations that imbue the nucleus with stretch sensitivity, thereby preventing an increased sensitivity to stretch and thus higher YAP signaling.
The Effectiveness of Rifapentine-Isoniazid in the Prevention of Tuberculosis Among HIV Infected Patients: A Systematic Review and Meta-analysis of Non-inferiority Randomized Trials
Qadar, Laila Tul, Shaik, A.A., Hegazi, M., Ahmed, Sophia , Asghar, Muhammad Sohaib , Yousaf, Zohaib

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3299-A3299

10.1164/ajrccm.2025.211.abstracts.a3299 Get It

Abstract Introduction: Tuberculosis (TB), a substantial cause of morbidity and mortality among human immunodeficiency virus (HIV) infected individuals, accounted for 161,000 deaths among HIV-co-infected patients in 2023. Tuberculosis preventive therapy can play a detrimental role in reducing the global burden. However, prolonged treatment duration compromises adherence and ultimately efficacy. This systematic review and meta-analysis aimed to assess the treatment adherence and effectiveness of rifapentine-isoniazid prevention therapy relative to the standard isoniazid therapy. Methods: This study was conducted following the PRISMA guidelines. A comprehensive literature search was conducted over PubMed/Medline, Google Scholar, Cochrane Library, and ClinicalTrials.gov from inception till 28 October 2024. Recruited articles were screened against the predefined inclusion criteria, and relevant data was extracted into a spreadsheet. Comprehensive Meta-Analysis (CMA) was used for data synthesis. Results: This meta-analysis included four studies containing data from 8,068 patients, with 5640 randomized to the rifapentine-isoniazid group while 2428 received isoniazid. Tuberculosis incidence varied from 0.21 to 2.0 and 0.63 to 1.9 per 100 person-years in the rifapentine-isoniazid arm and isoniazid alone group respectively. However, the pooled analysis showed a non-significant difference between the two groups (OR: 1.12; CI: 0.65 to 1.93; p=0.69) as shown in Figure 1. Similarly, no significant difference was noted across deaths in each group (OR: 0.76; CI: 0.43 to 1.34; p=0.35). While the two preventive therapies were non-inferior in terms of effectiveness, a significant improvement in treatment completion was observed with the rifapentine-isoniazid group (OR: 5.14; CI: 2.96 to 8.96; p<0.0001). Conclusion: The short-term rifapentine-isoniazid preventive therapy was non-inferior to the standard isoniazid therapy, however, a marked improvement in treatment completion was noted with the former.
Assessing the Utility of Provocative Maneuvers During Right Heart Catheterization in Pulmonary Venous Hypertension
Mendoza, Marco Patricio Bravo, Reddy, Yogesh N.V. , Hassoun, P.M., Hill, Nicholas S. , Erzurum, Serpil C. , Beck, Gerald J. , Finet, Emanuel, Jellis, C.L., Mathai, Stephen C. , Nishimura, Rick , Mathai, Stephen C , Frantz, Robert P. , Hassoun, P.M., Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rosenzweig, Erika B. , Mehra, Reena , Borlaug, Barry A. , Rischard, Franz

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3283-A3283

10.1164/ajrccm.2025.211.abstracts.a3283 Get It

Abstract Rationale: Although guidelines recommend the use of provocative testing to diagnose pulmonary venous hypertension (PVH) that is unapparent at normal resting right heart catheterization (RHC), the incremental value of provocative testing is unknown. We aim to evaluate the incremental diagnostic capability of inhaled nitric oxide (iNO), fluid challenge (FC) or invasive cardiopulmonary exercise testing (iCPET) to unmask PVH using previously defined hemodynamic cutoffs. Methods: We included subjects from the NHLBI-funded Pulmonary Vascular Disease Phenomics (PVDOMICS) study. Our analysis included patients with World Symposium on Pulmonary Hypertension (WSPH) Group 2 disease (G2PH) and G2PH comparators (WSPH Group 2 phenotype without a diagnosis of PH) as determined by the PI or adjudication panel. We then applied a protocol-driven provocative approach based on the feasibility of modalities available in most catheterization labs. Using a pulmonary capillary wedge pressure (PCWP) cutoff of >15, frequencies were identified for subjects based on resting PCWP and with iNO. Frequencies were also identified for: those who received FC with a PCWP cutoff of ≥18 or those who received iCPET with PCWP cutoff of >20 (upright) or >25 (supine). Results: There were 419 subjects identified with WSPH Group 2 disease (Figure). Roughly half were found to have a PCWP >15 during resting RHC (N = 207). Of the remaining subjects with a resting PCWP ≤15 (N = 150), 42 subjects were found to have a PCWP >15 with iNO administration (40.0%). Of the remaining 63 subjects with PCWP ≤15 following iNO administration, nearly half (N = 26, 48.0%) demonstrated a PCWP ≥18 following FC while 8 subjects (14.8%) demonstrated an elevated PCWP following iCPET. Conclusions: There is a high proportion of G2PH patients (∼35%) who appear hemodynamically similar to precapillary PH at rest. Inhaled nitric oxide vasodilatory challenge unmasks G2PH in many patients. In situations where iNO does not disclose the G2PH phenotype, provocation with FC or iCPET can be useful as a supplementary provocative maneuver. Future directions will focus on agnostically assessing the utility of provocation based on grouping subjects by resting hemodynamics as well as assessing the use of provocation in other forms of PH.
Association of Pulmonary Artery Dilation With Pulmonary Artery Pressure and Survival Using Updated Pulmonary Hypertension Hemodynamic Criteria
Couch, Taylor , Beck, Gerald J. , Erzurum, Serpil C. , Hill, Nicholas S. , Lempel, Jason K. , Nian, Hui , Schwalbach, Kevin T. , Terry, J.G., Group, The PVDOMICS Study, Rosenzweig, Erika B. , Carr, J. Jeffrey , Frantz, Robert P. , Hassoun, Paul M. , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz , Hemnes, Anna R. , Group, The PVDOMICS Study

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3279-A3279

10.1164/ajrccm.2025.211.abstracts.a3279 Get It

Abstract Rationale: Prior studies report association between pulmonary artery (PA) dilation on computed tomography (CT) imaging and pulmonary hypertension (PH). These studies predate expansion of PH hemodynamic diagnostic criteria and do not report patient mortality. As such, little is known about the presence of vascular changes in mild PH or their association with survival. We sought to investigate these relationships in individuals without significant parenchymal lung disease. Methods: We obtained CT images for subjects with group 1 or 2 PH, disease comparators, and healthy controls enrolled in the Pulmonary Vascular Disease Phenomics (PVDOMICS) study. We used Osirix imaging software to measure the main, left, and right PA (MPA, LPA, and RPA) and MPA:aorta (PA:Ao) ratio by diameter and cross-sectional area at locations consistent with prior studies. We evaluated associations with mortality and mean PA pressure (mPAP) using multivariable Cox and linear regression models adjusting for age, sex, and BMI. Descriptive statistics are presented as mean ± SD. Results: We identified 558 subjects (59 controls, 138 comparators, and 361 PH [267 group 1, 94 group 2]). 79 subjects had mPAP < 21 mmHg, 39 had mPAP 21-24 mmHg, and 371 had mPAP ≥ 25 mmHg. Increased MPA, LPA, and RPA diameter and area, PA:Aodia, and PA:Aoarea were associated with decreased survival (all p < 0.001) after multivariable adjustment. First versus third quantiles of all measurements were associated with mortality, with adjusted hazard ratio of 2.99 [95% CI 1.77, 5.05] for MPA diameter (2.84 vs 3.82 cm), 3.74 [2.07, 6.74] for MPA area (7.26 vs 12.74 cm2) and 5.24 [2.58, 10.66] for LPA area (4.55 vs 7.03 cm2). All measures significantly increased alongside PH severity from mPAP < 20 to 21-24 to ≥ 25 mmHg (see figure 1 for MPA diameter). All measures positively correlated with mPAP, including MPA diameter (ρspearman = 0.55) and PA:Aodia (ρ = 0.56). After multivariable adjustment, Q1 to Q3 increments in MPA diameter and PA:Aodia were associated with mPAP increase of 12.5 [10.7, 14.4] and 13.9 [11.9, 15.8] mmHg, respectively. BMI showed no correlation with PA size (ρ = 0.076 for MPA area, -0.051 for PA:Aodia). Conclusions: PA size increases alongside PH severity using updated hemodynamic criteria and is associated with incremental increases in PA pressure and mortality. LPA dilation demonstrates particularly strong association with mortality. PA size does not correlate with BMI. These novel findings enhance our understanding of vascular changes across the PH disease spectrum.
Social Determinants of Health Contribute to Adverse Clinical Outcomes in COPD Patients With Sarcopenia and Frailty
Bellar, Annette , Zein, Joe , Welch, Nicole , Dasarathy, S., Attaway, Amy , Hatipoğlu, Umur , Dasarathy, S.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3250-A3250

10.1164/ajrccm.2025.211.abstracts.a3250 Get It

Abstract Background. Sarcopenia (i.e. skeletal muscle loss) is a significant contributor to adverse clinical outcomes in patients with COPD. Nutritional intake and physical activity influence sarcopenia and frailty. There is increasing recognition that social determinants of health (SDOH) play critical roles in nutritional status. We evaluated the impact of SDOH on clinical outcomes in hospitalized patients with COPD and sarcopenia and/or frailty. Design. The Nationwide Inpatient Sample (NIS) (years 2018-2020) was analyzed to study adult hospitalized patients with a primary diagnosis of COPD (J43, J44). SDOH was defined by ICD-10 Z-codes as a composite sum of problems related to housing and economic status, unemployment, occupation, psychosocial, family, and healthcare access. Sarcopenia and frailty were defined by a composite of ICD10 codes that have been previously validated in the literature. Multivariate regression models were generated to determine the impact of sarcopenia, frailty, and sarcopenia+frailty on clinical outcomes in COPD patients, which were adjusted for age, race, sex, SDOH, and comorbidities (cardiovascular disease, anemia, coagulopathy, HIV, depression, diabetes mellitus). Results. Of the 282,164 COPD patients that were analyzed, 7254 (2.6%) had codes related to SDOH, 21,035 (7.5%) had sarcopenia, 106,995 (37.9%) had frailty, and 11,293 (4%) had both sarcopenia and frailty. The predominant SDOH code was related to housing (70.9%) followed by social environment (11.5%). SDOH codes were more prevalent in patients with sarcopenia alone (3.6%), compared with frailty (2.5%) or sarcopenia+frailty (2.6%) (p<0.001). When adjusted for demographics including age, race, and sex, SDOH was associated with greater odds of sarcopenia (adj OR 1.64, 95% CI: 1.51-1.79), frailty (adj OR 1.17, 95% CI: 1.11-1.24), and sarcopenia+frailty (adj OR 1.72; 95% CI: 1.54-1.90). COPD patients with sarcopenia+frailty had the greatest association with adverse clinical outcomes (i.e. in-hospital mortality, higher healthcare cost, and higher length of stay), followed by frailty alone, and sarcopenia alone (Table 1). Conclusion. In COPD patients, SDOH increased the odds for a diagnosis of sarcopenia, frailty, and sarcopenia+frailty. Sarcopenia+frailty had the greatest association with adverse outcomes in COPD patients, followed by frailty alone, and sarcopenia alone.
Increased Exacerbations and Hospitalizations Among PI[asterisk]MZ Compared to PI[asterisk]MM Individuals: An Electronic Health Record Analysis
Wang, Y. , Tremblay, Lauren S Munoz, Azzato, Elizabeth M. , Hutton, R., Wang, Xiaofeng , Ortega, Victor E. , Zein, Joe , Tejwani, Vickram , Baldomero, Arianne K. , Wendt, Chris H. , Attaway, Amy , Bowler, Russell P. , Hatipoğlu, Umur , Strange, Charlie , Stoller, James K.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3249-A3249

10.1164/ajrccm.2025.211.abstracts.a3249 Get It

Abstract RATIONALE The best described endotype of COPD is alpha-1 antitrypsin (AAT) deficiency, which is due to a genetic abnormality in the SERPINA1 gene. Homozygotes for the Z allele (PI[asterisk]ZZ individuals) carry the genotype most commonly associated with severe AAT deficiency, but a highly prevalent endotype is the heterozygous state (PI[asterisk]MZ individuals). Here we test the hypothesis that individuals with PI[asterisk]MZ genotype are at higher risk for COPD exacerbation and healthcare utilization compared to those with no pathogenic variants in the SERPINA1 gene (PI[asterisk]MM individuals). METHODS Real-world data on 4,456 individuals with available AAT genotyping were extracted from the Cleveland Clinic Health System (CCHS) electronic health records (EHR) and analyzed to compare the risk of moderate COPD exacerbation (defined as a short-term steroid prescription), all-cause emergent care (defined as an express care visit, urgent care visit, or emergency department visit), and all-cause hospitalization between individuals with PI[asterisk]MZ vs. PI[asterisk]MM genotypes. Cox proportional hazards models were used to adjust for age, sex, race, BMI, smoking status, comorbidity count, liver disease diagnosis, and median income by zip code.To assess the effect of AAT levels on outcomes, we categorized participants into three groups based on AAT level and used 90 mg/dL as a threshold given it is the lower limit of the normal reference range and genotype: MM individuals with an AAT level >90 mg/dL, MZ >90 mg/dL and MZ <90 mg/dL. To assess the effect of PI[asterisk]MZ genotype among individuals with pre-existing lung disease, we performed a subgroup analysis of individuals with at least a six-month inhaler prescription. RESULTS In this cohort, 308 individuals had a PI[asterisk]MZ genotype. PI[asterisk]MZ was associated with increased risk for moderate COPD exacerbations (adjusted HR [95% CI]: 1.66 [1.27, 2.17]) and hospitalizations (adjusted HR [95% CI]: 1.44 [1.19, 1.75]) compared to PI[asterisk]MM. The risk of hospitalization was higher among PI[asterisk]MZ individuals with AAT levels <90 mg/dL (adjusted HR [95% CI]: 1.59 [1.14, 2.23]) but not in those with AAT levels >90 mg/dL, as compared to PI[asterisk]MM. Sensitivity analysis in those treated with inhaler therapy showed overall similar results. CONCLUSIONS Increased hospitalizations and moderate COPD exacerbations among PI[asterisk]MZ individuals compared to PI[asterisk]MM individuals merit future prospective studies to better characterize the longitudinal course and healthcare utilization among those with an PI[asterisk]MZ genotype. Given the high prevalence of these carriers globally, PI[asterisk]MZ represents a COPD phenotype that invites additional investigation to identify biomarkers of worse disease and treatable traits.
Real-world Healthcare Resource Utilization and Economic Burden Associated With Idiopathic Pulmonary Fibrosis in Commercially Insured and Medicare Advantage Populations in the United States
Fee, Rebecca M. , Bui, B., Le, Lisa , Steffens, Andrea , Yang, Joseph Yuan‐Mou , Borah, Bijan J.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3204-A3204

10.1164/ajrccm.2025.211.abstracts.a3204 Get It

Abstract RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterized by chronic and progressive decline in lung function with unknown cause. Previous economic burden of IPF estimates were based on data from 2011 or earlier. Thus, more current estimates will help inform policymaking. This study aimed to quantify the healthcare resource utilization (HCRU) and direct costs associated with IPF, overall and by payer type (commercial or Medicare Advantage Prescription Drug [MAPD] plan). METHODS: This retrospective cohort study used the Optum® Research claims database from 01/01/2016 through 12/31/2023. Adult patients with IPF (defined as ≥2 claims with IPF diagnosis code within 365 days) were identified (IPF cohort), with the date of the first IPF medical diagnosis code set as the index date. A general population without IPF (control cohort) was exact matched to the IPF cohort in 1:4 ratio, based on age group, sex, geographical region, payer type (commercial vs. MAPD), and race/ethnicity. The assigned index date for the control cohort was the same as the index date of the matched IPF patient. Continuous enrollment of 12 months before and 3 months after the index date was required for both cohorts. All-cause and respiratory-related HCRU and direct costs were compared between the cohorts during the variable follow-up period, reported as observation time-weighted per-patient-per-month (wPPPM). RESULTS: A total of 7,670 IPF patients were exact matched to 30,680 control patients. The mean age was 76 years and 59% were male. HCRU during the follow-up was significantly greater across all categories in the IPF cohort compared to control cohort (p<0.001) (Table 1). The mean (standard deviation [SD]) wPPPM all-cause total healthcare costs were nearly four times higher for the IPF cohort compared to control cohort ($4,724 [$8,368] vs. $1,197 [$2,134], p<0.001). Hospitalization costs accounted for the largest proportion of all-cause medical costs for the IPF cohort (55%), whereas ambulatory costs were the largest for the control cohort (49%). The IPF cohort had significantly higher wPPPM pharmacy costs compared to the matched control cohort ($2,289 [$3,861] vs. $321 [$1,133], p<0.001) (Table 1). Similar trends were observed in respiratory-related HCRU and costs. When stratified by payer types, the total costs were significantly higher for commercially insured patients compared to patients with MAPD plan. CONCLUSION: The study demonstrated that patients with IPF incur higher economic burden compared to those without the disease, highlighting the need for more effective treatments to reduce costly healthcare resource utilization.
Clinical Outcomes of Patients With Idiopathic or Lymphocytic Hypereosinophilic Syndrome in the United States: A Real-world Retrospective Observational Cohort Study
Pongdee, Thanai , Dolin, P., Ding, Bo , Rowell, Jennifer , Edmonds, Carl, Eudicone, James M. , Moore, Andrew M. , Peer, Thomas , Chen, S.Y., Dolin, P., Jain, Priya Narayanan , Edmonds, C., Moore, A.M., Peer, T., Chan, K. Arnold

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3201-A3201

10.1164/ajrccm.2025.211.abstracts.a3201 Get It

Abstract RATIONALE: Hypereosinophilic syndrome (HES) is a group of rare diseases characterized by persistent hypereosinophilia causing organ damage/dysfunction. Idiopathic and lymphocytic HES (I-HES/L-HES) subgroups exclude clonal and reactive HES. We evaluated real-world clinical outcomes of patients with I-HES/L-HES. METHODS: This retrospective observational cohort study of patients with I-HES/L-HES collected data from the TriNetX Linked Network of de-identified Electronic Health Records plus Claims in the US. Patients had a HES diagnosis (ICD-10-CM: D72.11) between 10/01/2020–09/12/2023, with ≥12 months continuous enrollment before their first HES diagnosis record (index date [ID]). Patients with myeloproliferative/reactive HES, or a diagnosis of eosinophilic granulomatosis with polyangiitis after HES diagnosis, were excluded. Baseline was defined as 12 months prior to ID. Year 1 was defined as 12 months after ID. Patients were followed up until either 09/12/2023, disenrollment from insurance, death, or 24 months after ID, whichever came first. Clinical response was defined as ≥3 months without HES symptoms and a blood eosinophil (bEOS) count ≤750 cells/µL. Complete hematological remission was defined as a bEOS count ≤500 cells/µL. Partial remission was defined as a bEOS count <50% of baseline value, but >500 cells/µL. Kaplan-Meier curves estimated time to first HES flare and hematological remission. Analyses were descriptive. RESULTS: At ID, patients with I-HES/L-HES (N=110) had a mean (standard deviation [SD]) age of 43.8 (21.3) years; 66 (60.0%) were male, 58 (52.7%) were White and 30 (27.3%) were Black or African American. Mean (SD) follow-up was 15.1 (7.7) months. Median (95% confidence interval [CI]) time from ID to first flare (n=47) was 18.0 (11.0, not estimated) months (Table 1). Median (95% CI) time to first complete or partial hematological remission (n=52) was 15.3 (10.8, 21.6) months. The proportion of patients with a definite or probable HES flare was lower at Year 1 (10/69 [14.5%]) versus baseline (40/110 [36.4%]). Few patients achieved clinical response at baseline (10/110 [9.1%]) and Year 1 (5/69 [7.2%]). Among patients with bEOS data, mean (SD) bEOS count was 2235.3 (4351.7) cells/µL at baseline (n=51) and 833.6 (1396.0) cells/µL at Year 1 (n=11). The proportion of patients with a bEOS count <500 cells/µL was 20/51 (39.2%) at baseline and 7/11 (63.6%) at Year 1. CONCLUSION: Despite a reduced proportion of patients experiencing flares within a year after diagnosis, many did not experience hematological remission or clinical response by Year 1; suggesting high disease burden with existing treatment and the need for novel therapies to better manage I-HES/L-HES.
Unraveling the Role of Cell-free DNA as a Biomarker in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
Richert, Mary, Gao, Songqi, Keller, Michael , Bateman, Lori A. , Bleecker, Eugene R., Christenson, Stephanie A. , Meyers, Deborah A. , Ortega, Victor E. , Woodruff, Prescott G. , Curtis, J.L., Investigators, SPIROMICS, Christenson, Stephanie A , Kong, Hyesik , Jang, Moon Kyoo , Tian, Xin , Andargie, Temesgen Ewunetu , Bowler, Russell P. , O’Neal, Wanda K. , Martínez, Fernando J. , Curtis, J.L., Agbor-Enoh, Sean T.

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3192-A3192

10.1164/ajrccm.2025.211.abstracts.a3192 Get It

Abstract Rationale: Individuals with chronic obstructive pulmonary disease (COPD) have different clinical trajectories, some with minimal symptom burden, others experiencing recurrent exacerbations, the most severe of which require hospitalization. Existing diagnostics, including spirometry and symptom assessments, lack the precision to identify high-risk patients who may benefit from timely preventive therapies. Nuclear cell-free DNA (ncfDNA) is a well-established marker of systemic tissue injury, implicated in amplifying inflammation by triggering type 1 interferon release by activating DNA-sensing pathways. Because COPD is accompanied by inflammation and tissue injury systemically, we hypothesized that ncfDNA is associated with increased risk of severe exacerbations requiring hospitalization. Methods: Design: We utilized baseline plasma samples randomly selected from 672 individuals with COPD from the Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS) cohort, which prospectively collected exacerbation numbers and type. The primary endpoint was exacerbation requiring hospitalization. Secondary endpoints included total number of exacerbations (defined as use of oral steroids, antibiotics, or healthcare utilization) and severe exacerbations (defined as requiring emergency room care or hospitalization). Measure: We measured plasma ncfDNA using digital droplet PCR. Analysis: We assessed the association of ncfDNA with exacerbation outcomes using negative binomial regression or Cox regression, adjusting for age, percent post-bronchodilator forced expiratory volume in one second (FEV1), supplemental oxygen use, and smoking status. Results: In total, 57% (n=383) of COPD participants experienced exacerbations, 29% (n=197) at least one severe, and 22% (n=145) requiring hospitalization, the latter at a median of 622 days from enrollment (IQR=287-997). Higher ncfDNA levels at enrollment correlated with measures of COPD severity, including baseline FEV1 (beta = -0.12, 95% CI -0.18 to -0.049, p <0.001). Higher ncfDNA associated with increased risk of COPD exacerbation requiring hospitalization (incidence rate ratio (IRR) 1.40, 95% CI 1.12-1.75, p =0.003) and severe exacerbations (IRR 1.36, 95% CI 1.11-1.67, p=0.002) and a trend towards total exacerbations (IRR 1.11, 95% CI 0.98-1.26, p= 0.09). The primary outcome, risk of time-to-first hospitalization, correlated significantly with higher ncfDNA with hazard ratio (HR) 1.23, 95% CI 1.01-1.49, p=0.037. Conclusion: These results suggest that ncfDNA may serve as a predictor for severe and hospitalization-associated COPD exacerbations. To better understand the relationship between ncfDNA and COPD pathophysiology, follow-up studies should explore longitudinal trends and cfDNA tissue sources, and their link to COPD exacerbations.